Brokers Issue Forecasts for argenx SE -‘s FY2021 Earnings (ARGX)
argenx SE – (NASDAQ:ARGX) – Stock analysts at Wedbush cut their FY2021 earnings per share estimates for argenx in a research report issued to clients and investors on Monday, November 5th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($7.33) per share for the year, down from their previous estimate of ($6.63). Wedbush has a “Outperform” rating and a $125.00 price target on the stock. Wedbush also issued estimates for argenx’s FY2022 earnings at $3.21 EPS.
Several other equities research analysts also recently weighed in on ARGX. Stifel Nicolaus set a $139.00 price target on argenx and gave the stock a “buy” rating in a report on Thursday, October 25th. Evercore ISI assumed coverage on argenx in a report on Monday, October 15th. They issued an “outperform” rating and a $110.00 price target on the stock. SunTrust Banks increased their price target on argenx to $132.00 and gave the stock an “in-line” rating in a report on Tuesday, September 18th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $154.00 price target on shares of argenx in a report on Monday, September 17th. Finally, JMP Securities increased their price target on argenx to $150.00 and gave the stock an “outperform” rating in a report on Monday, September 17th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $131.00.
Large investors have recently made changes to their positions in the stock. Atria Investments LLC bought a new position in argenx in the second quarter worth approximately $213,000. Fred Alger Management Inc. grew its stake in argenx by 50.0% in the second quarter. Fred Alger Management Inc. now owns 3,000 shares of the company’s stock worth $249,000 after purchasing an additional 1,000 shares in the last quarter. Clear Harbor Asset Management LLC bought a new position in argenx in the third quarter worth approximately $326,000. Dimensional Fund Advisors LP bought a new position in argenx in the first quarter worth approximately $498,000. Finally, Northern Trust Corp bought a new position in argenx in the first quarter worth approximately $896,000. 56.10% of the stock is currently owned by institutional investors.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Read More: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.